NCT00350753已完成2 期
A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 126
- 试验地点
- 3
- 主要终点
- Objective response by RECIST criteria
研究概览
简要总结
Erlotinib and bevacizumab have shown activity individually, as single drugs, or in combination with chemotherapy in upper gastro-intestinal cancers, including esophageal and gastro-esophageal adenocarcinomas, gastric cancer and pancreatic cancer. Biomarkers indicating an important role of EGF and VEGF have been found in these tumors, and in cholangiocarcinomas as well. There is promise that combined treatment with erlotinib and bevacizumab is active and tolerable in a broad range of upper gastro-intestinal cancers, justifying an experimental phase II-study of patients with these diagnoses, refractory or intolerant to standard systemic therapy.
详细描述
Primary Objective
- To determine the median time to progression (TTP) and response rate (RR) of the combination of erlotinib and bevacizumab in patients with advanced upper gastro-intestinal carcinomas, refractory or intolerant to standard systemic therapy.
Secondary Objective
- To determine safety, tolerability and toxicity.
- To determine median and overall survival (OS).
- To correlate efficacy of treatment with the expression of tumor markers obtained in serum (EFGR, bFGF, p-VEGF-A, and sVEGF-R2), in paraffin embedded tumor tissue (micro vessel density (MVD), and expression of VEGFR and EGFR, after immunostaining), and in fresh frozen tumor biopsies (micro array-based analyses of patterns of gene expression).
Treatment:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically verified carcinoma of the gall bladder or bile ducts.
- •PS 0-1 (ECOG scale)
- •Age > 18 years
- •Life expectancy > 3 months
- •Sufficient organ function, defined as:
- •Platelets > 100 x 109/liter
- •Leukocytes > 3,0 x 109/liter
- •ACN > 1,5 x 109/liter
- •ASAT and/or ALAT < 3 x upper normal limit
- •Bilirubin < 1,5 x upper normal limit
- •EDTA clearance > 45 ml/min
- •APTT and INR < normal limit
- •Fertile females must use oral contraceptive, IUD (intrauterine device) or preservatives. Fertile males must use preservatives.
排除标准
- •Radiotherapy or chemotherapy within the last 4 weeks
- •Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids
- •Any prior EGFR- or VEGFR-based therapy
- •Any condition (medical, social, psychological), which would prevent adequate information and follow-up
- •Tumor located close to major blood vessels and judged to possess a high risk of serious bleeding
- •Any other active malignancy, except basal or squamous cell carcinoma of the skin, or carcinoma in situ
- •Any significant cardiac disease (New York Heart Association Class II or greater), significant arrythmia, congestive heart failure, acute myocardial infarction within 6 months or unstable angina pectoris
- •Clinically significant peripheral vascular disease
- •Evidence of coagulopathy
- •Use of ASA, NSAIDs or clopidogrel
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, anticipation of need for major surgical procedure during the curse of the study
- •o Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to treatment
- •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to treatment
- •Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound or ulcer
- •Pregnancy or breast feeding
- •Ongoing therapeutic anti-coagulation
- •Hypertension with blood pressure > 150/100 mmHg
研究组 & 干预措施
Erlotinib and bevacizumab
Experimental
干预措施: Erlotinib and bevacizumab (Drug)
结局指标
主要结局
Objective response by RECIST criteria
时间窗: From time of treatment start to response evaluation
Time to progression
时间窗: 1 year
次要结局
- Toxicity evaluated by NCI-CTCae version 3.0(1 year)
- Survival(1 year)
- Biomarkers(6 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerNCT00365391National Cancer Institute (NCI)27
已完成
2 期
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderGastrointestinal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00356889National Cancer Institute (NCI)56
已完成
不适用
A phase II study of erlotinib and bevacizumab in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) who have not received prior chemotherapy.on-Small Cell Lung CancerNL-OMON22641Roche46
已完成
2 期
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerNCT00126542National Cancer Institute (NCI)35
尚未招募
2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001non-squamous non-small cell lung cancerJPRN-UMIN000011791Itabashi Chuo Medical Center16